Published on 17 Aug 2023 on Zacks via Yahoo Finance

Sonnet (SONN) Up as Ovarian Cancer Drug Enters Clinical Study

Sonnet BioTherapeutics’s SONN shares rose 16.17% on receiving investigational new drug (IND) application clearance from the FDA to initiate a clinical study of its lead candidate, SON-1010, in combination with Tecentriq (atezolizumab), an immune checkpoint inhibitor developed by Roche RHHBY. The combination study will be evaluated in a phase Ib/IIa study on patients with platinum-resistant ovarian cancer.

The early-mid stage therapy is referred to as SB221, which is a global, dose-escalation study assessing the safety, tolerability and efficacy of SON-1010, in combination with Roche’s atezolizumab. Part one of this two-part study recently started enrolling patients in Australia. The IND clearance enabled a wider global reach for the study and will potentially accelerate patient recruitment through the involvement of U.S. trial sites.

In January 2023, Sonnet and Roche entered into a collaboration agreement to develop the combination of SON-1010 with atezolizumab for patients with ovarian cancer.